Phospholipids pp 115-122 | Cite as

Phospholipid Liposomes as Drug Carriers: Preparation and Properties

  • Herbert Stricker


Phospholipids such as Phosphatidylcholines have the tendency to form molecular bilayers and to minimize their surface by forming vesicles. Such liposomes have been tested with regard to their suitability as drug carriers. The number of drugs which has been entrapped into liposomes up till now is considerable. The main groups of interest today are: cytostatics, antibiotics, biological response modifiers and hormones. With some of these preparations clinical studies are now being carried out. Examples are: liposomes containing Amphotericin B, or Adriamycin, or lipophilic derivatives of Muramyldipeptide, etc. Many publications have been written about the properties of liposome-entrapped drugs and the biological effects which can be achieved with them2,12. From today’s point of view it is clear that liposomes as a dosage form have significant biopharmaceutical advantages, but only in specific fields (e.g. parenteral depots, drug targeting via the reticuloendothelial system, RES, etc.)


Entrapment Efficiency Vesicle Size Biological Response Modifier Soybean Lecithin Liposome Preparation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Arndt, D. and Fichtner, I., 1986, “Liposomen”, Akademie Verlag Berlin.Google Scholar
  2. 2.
    Gregoriadis, G., 1984, “Liposome Technology”, CRC Press, Boca Raton.Google Scholar
  3. 3.
    Ostro, M.J., 1987, “Liposomes”, Marcel Dekker, Inc New York, BaselGoogle Scholar
  4. 4.
    Kibat, P. and Stricker, H., 1986, Storage of Dispersions of Soybean Lecithin Liposomes, Pharm. Ind. 38:1184–1189.Google Scholar
  5. 5.
    Kibat, P. and Stricker H., 1988, Elimination of Liposome-Encapsulated Substances Following Intravenous Administration, Arzneim.Forsch./Drug Res., 38:1472–1478.Google Scholar
  6. 6.
    Mentrup, E. and Stricker, H., 1990, Herstellung von Liposomen mit einem Hochdrucksterilisator, Pharm. Ind. in press.Google Scholar
  7. 7.
    Mentrup, E., Butz, P., Strieker, H. and Ludwig, H., 1988, High Pressure Sterilisation of Liposomes, Pharm.Ind. 50:363–366.Google Scholar
  8. 8.
    Mentrup, E., Strieker, H., Wowra, B., Zeller, W.J. and Sturm, V., 1989, In vitro Release and Depot Effect after Intratumoral Application of Metrizamide-containing Liposomes, Arzneim.Forsch./Drug Res., 39:421–423.Google Scholar
  9. 9.
    Weckenmann, H.P., Matzku, S. and Strieker, H., 1988, Optimization of the Covalent Binding of Monoclonal Antibodies to Liposomes, Arzneim.Forsch./Drug Res., 38:1556–1563.Google Scholar
  10. 10.
    Weckenmann, H.P., Matzku, S., Strieker, H. and Sinn, H., 1989, Stability in Biological Fluids and Clearance of Immunoliposomes, Arzneim.Forsch./ Drug Res., 39:415–420.Google Scholar
  11. 11.
    Wowra, B., Mentrup, E., Zeller, W.J., Strieker, H. and Sturm, V., 1988, CT-Kinetik intratumoraler Liposomendepots, Onkologie, 11:81–84.PubMedCrossRefGoogle Scholar
  12. 12.
    Yagi, K., 1986, Medical application of liposomes, Japan Scientific Societies Press, Tokyo.Google Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • Herbert Stricker
    • 1
  1. 1.Institut für Pharmazeutische Technologie und BiopharmazieUniversität HeidelbergGermany

Personalised recommendations